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ABSTRACT
This paper discusses the scientific and technological factors that
coincided in the beginning and in the initial development of the phar-
maceutical industry in Europe. Having pointed out the reasons that
favoured the initial success of the German chemical pharmaceutical
industry, we evaluate the efforts of other countries to occupy the lead-
ership of this industrial sector: from the British trials of business con-
centration to all the strength of the Swiss as a neutral nation in con-
flicts of war; a special tractor will be dedicated to the study of the
penetration of German industry in France, in particular, in the sys-
tems invented by German manufacturers to violate the French pro-
tectionist legislation. In concluding, we describe the two industrial-
ization models followed by the pharmaceutical industry during the
decades of change of the 19th-20th centuries. We evaluate and explain
the social, economic, cultural and, above all, scientific-technical rea-
sons that defined both and discuss the motives that led to the current
situation of leadership of the central European model in the pharma-
ceutical sector.
Keywords: Pharmaceutical industry; history; Europe.
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REVISIÓN
RESUMEN
Innovación vs. tradición: la elección de un modelo de industria-
lización farmacéutica en la Europa de los siglos XIX y XX.
Analizamos los factores científicos y tecnológicos que confluye-
ron en el inicio y primer desarrollo de la industria europea del me-
dicamento. Tras señalar las razones que favorecieron el auge inicial
de la industria químico-farmacéutica alemana, pasamos a valorar los
esfuerzos de otros países por ocupar el liderazgo de este sector in-
dustrial: desde los ensayos británicos de concentración empresarial
hasta la potencialidad de Suiza como nación neutral en los conflic-
tos bélicos; un capítulo especial queda dedicado al estudio de la pe-
netración de la industria alemana en Francia, en particular, a los sis-
temas ideados por los fabricantes alemanes para violar la legislación
proteccionista gala. Para concluir, caracterizamos los dos modelos de
industrialización seguidos por la industria farmacéutica durante el
gozne de los siglos XIX y XX; se valoran y explican las razones so-
ciales, económicas, culturales y, sobre todo, científico-técnicas que
les definen y se discuten los motivos que condujeron a la actual si-
tuación de liderazgo del modelo centroeuropeo en el sector farma-
céutico.
Palabras Clave: Industria farmacéutica; historia; Europa.
1.  INTRODUCTION
The stages that define process of industrialisation in Europe are
not uniform; their differences have their roots, as wisely pointed out
by the German sociologist Max Webber at the beginnings of the 20th
century (1) in the ‘spirit of capitalism’ which defines the countries of
the centre and north of Europe, with the ‘traditionalist’ temperament
of the Mediterranean Europe. The different mentality and the differ-
ent rent per capita with which the countries of the centre and north
of Europe (the ‘Protestant Europe’) faced the ‘industrial revolution’ as
opposed to those washed by the Mediterranean (the ‘Catholic Euro -
pe’), is undoubtedly.
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The genesis of the European pharmaceutical industry is not indif-
ferent to this situation as a whole; even though, together with the so-
cial factors, economic or political definers of any type of industrial ac-
tivity others of a scientific and technological character should be
considered as well. Among the most important is the appearance of the
active principles of synthesis and semi-synthesis as well as the arrival
of new pharmaceutical forms, more adaptable to the requirements of
large-scale elaboration demanded by the new pharmaceutical industry.
From the middle of the 19th century, the industry of active princi-
ples and, above all, those relative to chemical synthesis of medicines
from carbon, were dominated by Germany, thanks to the hegemony
in the field of organic chemistry of industrial application. Other coun-
tries in central Europe, such as Switzerland, or those of Anglo-Saxon
culture such as England, also tried to get a look into this market, prin-
cipally after the outbreak of the First World War.
The Mediterranean Europa —France, Italy or Spain— could never
compete with the large pharmaceutical chemical industries established
in ‘Protestant Europe’; their contribution to the development of the drug
industry would come with the adaptation of pharmaceutical tradition
to large-scale elaboration, principally through the creation of new serv-
ices of forms of drugs and the industries for their commercialisation.
The modernisation of pharmaceutical technique came about in the
last 30 years of the 19th century as a result of the efforts of the phar-
macy collective at an attempt at compatibility with the traditional
modus operandi and the new scientific doctrines. With the exception of
injectable vials, invented in 1886 after the development of asepsis, the
new pharmaceutical forms which would revolutionize the therapy and
the professional habits of medical and chemists professionals, came into
being throughout the long period between 1833 and 1853. During this
time, the principal forms of oral administration were invented: gelatine
capsules (1833), pills (1843) and amylaceous capsules (1853).
The perfection of these preparations was intimately linked to the
birth and development of the drugs industry as their elaboration was
undertaken with the use of specific machinery. The existence of forms
for the drugs is therefore, necessary for their industrial development.
However, and although this seems paradoxical, these were not invent-
ed by the large pharmaceutical laboratories but by the chemists, in
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an attempt to resolve old pharmaceutical problems and to adapt the
dispensary tactics to the new sciences of health. This modernisation
of the professional collective of pharmacy was made use of by the
drugs industry for its own development. In effect, both traditional
pharmaceutical preparations as well as the modern pharmaceutical
forms appearing in the last 30 years of the 19th century would be sub-
jected to a profound technological recycling in order to accelerate and
make the process of production profitable (2, 3).
In the following pages we will try to discern and typify most mod-
els of industrial development. We shall endeavour to define what the
characteristics are that, from a technical option, define both models.
The drugs industry presents some of its own characteristics that dif-
fer from the chemical industry, to which they tend to be united con-
ceptually. It is certain that both have in common —although more so
today— the use of processes of similar production, but they differ —
more so in the past— in the finality itself of the finished product. The
drug is not always of chemical origin and for this its industrialisation
process is not strictly comparable with that of the chemical industry
in general. The specificity of the pharmaceutical industry is closely
related to the final aspect with which the drug is presented, the phar-
maceutical dosage form (4).
The European chemical industry has been the object of a great
number of studies, some of which have centred on strictly technolog-
ical aspects or of industrial projection (5, 6), others have attacked the
problem from an economic or political viewpoint (7, 8), although oth-
ers have compared the models of industrialisation followed by differ-
ent European countries (9, 10). Our work attempts to deal with the
peculiar characteristics of the pharmaceutical industry, whose origin
resides in the existence of a professional group dedicated, previous to
the appearance of manufacturing processes, to the artisan elaboration
of medicines. The models of compliance of these professionals, to new
industrial techniques, is the object of this paper.
2.  THE INNOVATION: THE CENTRAL-EUROPEAN MODEL
From the last quarter of the 19th century, chemical industries be-
gan to take on an importance in the consolidation of the European
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capitalist system, which until then had been limited to textile manu-
facture, the iron and steel industry and mining.
At the beginning of the First World War, German predominance in
the chemical sector was unquestionable; no other world power was
able to compete with the German giant. German leadership was evi-
dent from 1871 on, dating from the end of the Franco-Prussian war
and the commencement of German unification. The main field of ac-
tion was that of dyestuff industries, appearing in the middle of the
19th century, due to the reuse of residues originated in the operations
of distilling bituminosus coal distillation. With reference to the organ-
ic chemistry industry in particular, more than half the total of the
chemical production exported by Germany in 1912 corresponded to
dyestuffs, perfumes or drugs, and the sales abroad of these products
exceeded the total figure of exports in the rest of the world (11). This
was, without doubt, the golden age of the German chemical industry,
after which the figures descended gradually due to competition of oth-
er countries such as the United States, France or England. In 1916,
there were 4.000 chemical remedies synthesised in Germany (more
than 200 were the most used and exported), representing the greater
part of those existing in the world and which were produced in no
less than 20 large factories (12). In 1924 the German contribution to
the world market of synthetic dyestuffs was barely 40% of the exports,
although still the highest in the world, they had dropped considerably
(13). This productive centres basing their activities on the tars ob-
tained from diversity was not capricious. They were coaltar, residues
from other industries and at the same time raw materials for the elab-
oration of these articles and others, as important for national defence
as the explosives. This concept of integrated chemical industry is es-
pecially useful for the understanding of the tentacular scheme of en-
terprises in the cleaning industry.
The devastating advance of the German chemical industry would
have repercussions especially in those countries which, until then, had
been leaders in this market. The most representative case perhaps is
that of England; leader of this industry during the central decades of
the 19th century, it underwent a progressive deterioration, almost in-
versely proportionate to German growth, and would acquire almost
critical overtones during the change of the century. The conflict of
1914 would oblige them to carry out a profound examination of con-
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science, aimed at analysing and attempting to meet the enemy, with
both the arms of science and industrial progress.
The British effort was worthy of praise, although not as produc-
tive as would have been wished; the self-critical analysis of the caus-
es that provoked industrial weakening and the possible recipes for
 trying to palliate their disadvantageous situation with respect to Ger-
many, were amply debated subjects in scientific, commercial and po-
litical forums throughout the first quarter of the 20th century. The key
to their failure was the same that had propitiated the German tri-
umph: namely, industrial scientific training at high level and develop-
ment of applied research. The solutions to overcome this situation lay,
obviously, in the emulation of the only possible model, that followed
by Germany, eg., the design of an ad hoc educative infrastructure, and
entrepreneurial investment in chemical research.
The manufacture of dyestuffs is a paradigmatic example of this sit-
uation. This industry, born in England after the discovery of mauveine
by William Henry Perkins, was soon to be snatched from them (14). In
1913, England imported 17.000 tonnes of artificial dyestuffs, of which
90% corresponded to operations in which Germany was the remittent
and the remainder came from Switzerland. In an attempt to lift this de-
pendency, at least partially, possibly for motives of national pride, the
British government became involved in a project to create a national
industry of dyestuffs with state capital. This project took the form of
The British Dyes Co. Ltd., which, after its fusion (1918) with other fac-
tories, became known as British Dyestuff Corporation. With a very strong
protectionist policy against colouring materials made outside England,
this Society started off its career in the difficult market of derivates of
coaltar (15). The British effort was to produce an important increase in
these products and a descent in importations, although at the cost of
an important deficit originating from multiple factors, among which an
insufficient domestic market and the rather weak uncompetitive export
resources can be highlighted, precisely, associated to the protection
measures laid down by the British government.
Following in the footsteps of Germany, England attempted to re-
solve these problems by means of business concentration. The results
of these efforts were an integrated British Chemical, formed by the
merger of the United Alkali Co., the Nobels Co. and the Brummer Mond,
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capable of assuming not only the production of dyestuffs but also fer-
tilisers, explosives, sulphuric acid, etc. (13, 16). In spite of all the dif-
ficulties, more so, if we compare them with the Mediterranean Euro-
pean countries, England continued to be an important power in the
chemical pharmaceutical industry and drug sector.
Chemical drugs also sustained a considerable development in
Switzerland especially in Basle, one of the most important nuclei of
the world chemical pharmaceutical industry (12). The upsurge of
Swiss dye industries during the first 15 years of the 20th century, a
specially negative period for this type of activity in France and Eng-
land, can be explained by a cumulous of circumstances of synergistic
effect: specialisation in the fabrication of products, some of which
were authentic monopolies; quality of the commercialised products,
partly due to acceptable research planning; permissiveness and col-
laboration with the German dying industry; and greater facility for
the sale of its production due to its condition of neutrality.
The typical pharmaceutical dosage forms used by the pharmaceu-
tical industries in the Central-European countries was tablets. We owe
the invention of tablets to the Englishman William Brockedon who,
on December 1843, patented this product in his country under the
domination of “Shaping pills, lozenges and black lead by pressure in
dyes”. His intention was to eliminate from the pill formulation all the
excipients, generally of a glutinous cohesion nature which made the
later desegregation dissolution and internal absorption of these prepa-
rations more difficult. On general lines, the idea of Brockedon was
formed by a cylindrical compressor, a matrix and mortar, which the
author himself would describe exhaustively in the text corresponding
to the patent of his invention (17, 18). The operation that characteris-
es this pharmaceutical form and allows the preparation to be convert-
ed in the most adaptable way for the requirements and the technolo-
gy of the new medicinal industry. The fabrication of tablets is,
essentially, industrial. If at any time dispensary elaborations were car-
ried out, principally in the countries of the European Mediterranean
area, these were made possible thanks to the adaptation of manufac-
turing technology to the necessities of the chemist.
The pharmaceutical form invented by Brockedon remained inert
for nearly 30 years. During the period 1843 to 1872, work relative to
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this invention, and possibly its improvement, was little and of scant
relevance. The year 1872 can be considered as the real takeoff of the
elaboration of tablets, with the presentation by the German Isidor
Rosenthal of a new system of manual compression, based on the ac-
tion of a screw press which supplied the compression force (19). These
machines opened a new page in the history of drugs, and began a
process of improvement and popularisation unknown till then by any
pharmaceutical preparation.
If Germany became one of the principal suppliers of this new tech-
nology to the pharmaceutical world, the other was the United States.
The Americans, in the same way that the teutons had done, developed
their own procedures of compression, competing directly, in space and
in time with German technology and, contrary to what happened with
the latter, taking into account the first English patents. North Ameri-
can research in this field gave fruit and this time the technological in-
novation would be truly original; on the one hand the manual lever
press (1879) and on the other, the excentrical and vertical tableting
compressor machine (1874) also activated manually but with the vo-
cation of being able to transform itself or influence in future automat-
ic inventions. Two technological proposals that would compete during
the last quarter of the 19th century, with the German screw press, in
an endeavour to achieve hegemony which was exclusively based on cri-
teria or parameters of mechanical origin. The German-North Ameri-
can competition in this field should not be understood to be based on
reasons or postulations of a strictly pharmaceutical type, focused on
obtaining a final product of formulation, desegregation, solubility and
optimum stability but rather on arguments of technological basis, more
concerned with engineering than pharmacology (20, 21).
The tools used to carry out the elaboration of tablets respond es-
sentially to one same reason, sustained on two premises which, in our
opinion, are fundamental for understanding the success of this phar-
maceutical form and its excellent industrial implantation: the tenden-
cy towards the unification of all the procedures of pressure and the
search for processes of continual function, capable of achieving a to-
tal automation of the machinery (17, 22).
Another pharmaceutical dosage form used by the Centro-European
industries was a rebirth of the french capsules, adapted in the 1870s
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for dealing with large-scale elaborations. The North American phar-
macist, Frederick A. Hubel was probably, the first to prepare, around
1874, hard gelatine capsules on wholesale scale using a mechanical
device, manufactured by himself, which would be subject to succes-
sive improvements until finalising in the first patent for an apparatus
of this type (1877). The period 1877-1883 was the most fertile time as
regard to patents for capsule making machines, and the years imme-
diately following these are those of final consolidation of the great in-
dustry of hard gelatine capsules (23, 24). At the beginnings of the 20th
century machinery had already displaced the manual worker. There
were those who gave ‘objective’ reasons for choosing mechanical pro-
cedures in detriment of the artisan, based on criteria of uniformity,
appearance, solubility, stability and profitability. The success of the
procedures for manufacturing hard gelatine capsules among the main
drug industries resides on the suitability of the different stages that
this type involves and the technological possibilities of the machinery
used. The great achievement is separating the phases obtained by the
capsular support and the closed filling in two totally independent in-
dustrialised processes. Given the difficulty of agglutinating these op-
erations in the same machine, it was decided to give the elaboration
of empty capsules to firms specialised in this matter.
3.  THE TRADITION: 
THE EUROPEAN-MEDITERRANEAN-MODEL
The fragility of the French chemical pharmaceutical industry com-
pared with that of Germany was evident, mainly in reference to or-
ganic chemistry. On the reverse, both the inorganic chemistry indus-
try as well as that relative to pharmaceutical specialities were perfectly
competitive, and on occasion, free. As we have commented, the sci-
entific and commercial imbalance of Germany in the drugs sector was
constructed on approaches of global chemical development, quite the
contrary to the French case, where the drug industry held its own
identity. The global results gave an advantage to Germany, making it
capable of invading the world with new active pharmacological mol-
ecules and, the ability to adapt these industrial formats, both classic
and modern. The experience and tradition of French pharmacy only
gave it a certain chance in the market of finished products and in
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those of inorganic basis. It showed deficits however and was depend-
ent on their German ‘enemies’ for all the necessary raw materials with
which to elaborate their chemical drugs.
The imbalance in this speciality is translated into the existence of
a single factory of artificial dyestuffs, of French capital, capable of
working from basic raw materials. We refer to Société anonyme des
matières colorantes et produits chimiques de Saint Denis, founded in
1881, by merger of the Poirrier (1830) and Dalsace (1843). The rest
of the French establishments could only deal with the manufacture
of dyestuffs using intermediate products of Germanic origin; this is
the case of Fabrique de Couleurs d’aniline et Raffinerie de Beuzines
Victor Steiner, the Fabrique de Produits chimiques et Matières col-
orantes Mabboux et Cammel and the Manufacture de Matières col-
orantes Laroche et Juillard. To these four companies, we should also
add the Compagnie nationale de matières colorantes et de produits
chimiques, a national project, promoted by the Syndicat national des
matières colorantes, in the same line as the British Dyes and with sim-
ilarly ambitious aims.
Faced with a scarcity of purely French manufacturers, others were
able to find a place, either by means of acquisition, or through im-
plantation in French soil acting as subsidiary or branch of the large
German and Swiss firms. They were only finalisation factories in
which intermediate products were used coming from Germany, and
susceptible to conversion into dyes with a simple chemical operation
of transformation. In this way, the large German houses of dyestuffs
obtained a double profit: outwitting customs norms which prohibit-
ed the entrance of any supposedly medicinal product either unde-
clared or not included in the pharmacopoeia, thus enabling the pay-
ment of reduced tariffs, applicable to raw materials not existing in
French territory. Also, they continued to maintain their privileged sit-
uation by retaining, confined and protected, the procedures and tech-
niques of fabrication in Germany.
But German colonisation was even more evident in the case of
drugs ready made for consumption. In this case, the system used was
that of the prate-nom, i.e French pharmaceuticals established in the
country who prepared and/or sold drugs supplied by their German as-
sociates (25). The mechanism consisted in elaborating pharmaceuti-
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cal specialities prepared from German associates, on French territo-
ry, thanks to the existence of these figureheads. These would then be
sold in France and Germany as if they had been French prepared, in
accordance with the Convention of Bern. The results were much more
beneficial for the German industrialists, as they managed to export
their merchandise and avoid their own pharmaceutical legislation
which prevented them from selling drugs ready for consumption at
another price other than the official tariff. Despite a notable expan-
sion, in the form of chemical subsiduaries established in French soil
and through prête-noms pharmaceuticals, France continued to carry
an important weight in the drugs industry.
Contrary to what had happened with the German chemical drug
industry, the French laboratories were, for the greater part, specifical-
ly pharmaceutical either in specialities or in chemical products and
their qualified personnel included many medicals, biologists and phar-
macists as well as the chemists and chemical engineers, also present
in German industry.
As an answer to the triumphant apparition of tablets in the drug in-
dustry, French pharmacy was to concentrate its interest on another two
new pharmaceutical forms: the soft gelatine capsules and the cachets.
While the former responded to a pure industrialised model, which in
the end would not last due to be unstoppable rise in hard gelatine cap-
sules, the cachets arise as the most modern banner of the traditional
pharmacy (26). With the advance of technology and the establishment
of procedures of large scale drug manufacture in full swing, this phar-
maceutical form, clearly homemade, and poorly adapted to wholesale
production, appears.
Gelatine capsules were invented by the French pharmacist Fran -
çois Achille Barnabe Mothes in 1883, with the aim of disguising the
medicinal substances of disagreeable organoleptic propieties. The
method invented by Mothes, was based on the immersion of ovoid
metallic moulds in baths of liquid gelatine, a troublesome process,
which required great manual skill and was not very productive. These
limitations facilitated the development of new systems of encapsula-
tion, more in accordance with industrial imperatives that began to be
in vogue in most developed countries. The proposal of the French
pharmacist Viel (1844) was in this context and constituted the first
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really interesting variant since the invention of the new format. The
basis of his technique relied on obtaining medicinal capsules by means
of a simple mechanism, capable of elaborating cylindrical hollow bod-
ies of gelatine by sliding them into a mould and in whose interior the
medicinal substance was kept. These cylinders of gelatine could be
submitted to capsular division thanks to the use of a cutting instru-
ment specially designed for this operation. The perfection of the tech-
nique of capsular elaboration meant a truly gigantic step forward with
the validation of a new French patent presented by Lavalle and
Thévenot in 1846. The basis of this new method, clearly influenced
by the procedure carried out two years before by the Italian Pegna,
was the fabrication of capsules by interposition of the medical sub-
stance between two plates of solidified gelatine, fused by pressure of
metal plates with holes (capsular moulds).
Parallel to the proposal of Thévenot was another developed and
defended by yet another Frenchman, Jules César Lehuby; a new in-
vention self-denominated as Mes enveloppes médicamenteuses, which
would later be patented in France in October of 1846. Lehuby would
describe these ‘envelopes’ as similar to the cocoons of silk worms,
formed by two adjustable compartments one within the other until
making a form like a cylindrical box capable of containing the re-
quired medical substance in its interior. The revolutionary invention
of Lehuby, at that time known by the name of hard gelatine capsules,
was modified by its author three consecutive times (1847-1850) with
the aim of improvement. Despite the fact that Lehuby was really the
inventor of the double compartmental gelatine capsules, other au-
thors, principally from the Anglo-Saxon area, would concede the priv-
ilege of invention to the British James Murdoch, responsible for a
patent for “an improved capsule or small care for protecting matters
enclosed therein from the action of air, and an improved material to
be used in their manufacture” (May 1848). Murdoch himself recog-
nised, in the preamble to the text of his patent, that his contribution
was not totally original: “it was communicated to me from abroad”
(24). One of the possible reasons to explain this error of attribution,
maintained by the greater part of the texts on the subject of gelatine
capsules written at the end of the 19th century, and even today (27),
was the scant repercussion that this type of preparation had during
nearly 30 years following the publication of the first patents. The cap-
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sules of hard gelatine were specially indicated as a support of solid
medicines, which were less used at this time than the liquid forms
and, therefore, only needed moderately high productions in order to
profit from the construction of capsular moulds. 
The amylaceous capsules made their appearance in France in the
middle of the 19th century as a pharma-technical answer to certain
problems of solubility that some covered pills represented. In 1853,
the French man André Alexandre Guilliermond proposed a new phar-
maceutical form which he called enazyme, as a result of closing a pre-
viously flattened pill, between two discs of unleavened bread approx-
imately two centimetres in diameter and hollowed in the centre, which
were then soldered by pressure after moistening the discoidal edges.
The enazyme of Guilliermond did not have much repercussion in the
pharmaceutical world until 20 years later. In 1873, Stanislas Limou-
sin, also French, presented, first to the Societe de Pharmacie de Paris
and later to the Académie Nationale de Médecine, a new pharmaceuti-
cal form, basically very similar to that proposed in 1853 by Guillier-
mond, which he named cachets médicamenteux (28). The Limousin’s
cachets were capable of hiding the disagreeable odours and tastes of
some drugs, by avoiding the interactions of drug and excipient due to
the absence of the latter. They could be used in a great number of
drugs, due to the possibilities offered by the technical proposals for
filling, closing and sealing that he had elaborated. The success of Lim-
ousin lay in generalising the elaboration of amylaceous capsules by
the previous establishment of technological keys that would propiti-
ate their existence, that is, while the enazyme of Guilliermond is only
the final result of our specific pharmaceutical operation, the essential
in the Limousin’s idea is the pharmaceutical form, the cachet, usable,
generally speaking, for any drug. The evolution of traditional pharma-
cy towards the drug industry had already begun.
Injectable vials was a particular and integrated pharmaceutical
dosage form; the inyectable were invented in 1886, by the French
chemist Stanislas Limousin (29). Their magnificent reception among
european pharmacists of the Mediterranean area was due to the hand-
made character of this pharmaceutical form and the artisan manner
of carrying out this type of preparation. Perhaps for this, the name
that has lasted has been that of the Latin root Ampullae and not that
of Amphiolen or Einschmelzgláser, proposed by the German Pharma-
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cy. The bottling and filling process of the medicinal liquid in the glass
vial constitutes the most characteristic and definitive stage in the man-
ufacture of injections, at least from the pharmaceutical point of view.
We are faced with an operation, or group of operations, which are to-
tally innovative for pharmaceutical procedure. We believe that the im-
plantation and evolution of the different systems of filling marked a
point in the progress of this pharmaceutical form, going from totally
artisan practices to industrial procedures (30, 31).
4.  CONCLUSION
The therapeutic revolution of the 19th century was not lived in the
same way in all countries; the economic social and cultural tradition,
was key for interpreting the conceptual change that the discovery of
natural active principles and the preparation of new synthetic reme-
dies from bituminosus coal, supposed. The Central European coun-
tries were very involved in the mechanisms and in the philosophy of
the industrial revolution. Soon they were to control the fabrication of
new drugs. The industry of alkaloids and that linked to organic syn-
thesis of pharmacologically active molecules was very soon dominat-
ed by the countries of this area, especially by Germany, although oth-
er nations also played a part, namely Switzerland and England.
Although it is certain that with the synthesis of alkaloids, the
launching of industrialised medication took off, the definitive backup
was produced with the development of organic chemistry of pharma-
ceutical application. In the first case, the research protagonist is ob-
viously therapeutic: the extraction of active principles is no more than
an optimisation of classic medicinal material. In the second case, the
drug is only a secondary product obtained or attainable from the pro-
cedures used in any chemical industry.
The ‘innovative’ scheme for drugs, generalised in Central European
countries, follows general industrialisation guidelines; specific facto-
ries do not exist for their attainment but they are integrated into much
more viable commercial and technological units such as those respon-
sible for the elaboration of artificial dyestuffs. The chemical industry
functions as a whole; each raw material used in a specific process may
not be more than the product or waste of another. In these conditions,
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the elaboration of chemical drugs cannot be improvised and has to
be subject to a general industrial flow chart.
In this model, the pharmaceutical industry does not exist, at least
understood as an easily identifiable sub-sector; the preparation of
drugs is carried out in factories in which, in addition, explosives,
dyestuffs, perfumes, photographic material are also elaborated. The
birth of German or Swiss pharmaceutical industries is chemical; only
those laboratories created as a result of the breakthrough with alka-
loids, the cases of Merk-Darmstad or Schering are two good examples,
originating in apothecaries, the rest proceeded from the evolution of
other less specialized fabrication centres (Agfa, Bayer, Hoescht, Ciba,
Geigy, Sandoz, etc.). The break through of new pharmaceutical forms
and the application of French machinery would come later, when
chemical infrastructure had already been consolidated, favouring the
development of the pharmaceutical speciality more linked to the great
chemical laboratory than to the professional collective of pharmacists.
The fundamental axis of the ‘traditional’ model is pharmacy, un-
derstood as a highly qualified profession but also as a scientific dis-
cipline on its own. This premise is extremely useful for understand-
ing the principal characteristics of the pharmaceutical industry in the
countries of southern Europe; its objective is medicine and this can
never be a sub-product attainable as a result of ordinary processes of
industrial chemistry. In these factories the drug is the protagonist and
its preparation is, generally, the only line of possible activity in this
type of laboratory.
For the large factories of German dyestuffs, medicines appear as
the result of general chemical planning or as another object in a di-
versified superstructure in need of an adequate covering, of pharma-
ceutical form, for its commercialisation. For the French industries the
covering is the final aim and the chemical substances are no more than
raw materials with which to elaborate the end product. While the med-
icine industry in Central European countries is essentially, pharmaceu-
tical chemical, that of the European Mediterranean countries tends to-
wards pharmaceutical specialities and while the former depends on
organic chemistry, the latter depends on pharmaceutical technology.
Laboratories of pharmaceutical specialities are born from the su-
per-production of the chemist’s shops at a time marked by the prescrip-
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tion of specific generalised remedies for pathologically homogeneous
populations. This would explain the movement of the Mediterranean
pharmaceutical industry towards exclusively inter-professional capital-
isations. The structures of their laboratories do not derive from Lim-
ited Companies, but family enterprises with pharmaceutical capital or
arising from chemist‘s shops and directed commercially and technical-
ly by professionals of the drug business.
The decisive implication of the chemist in the Mediterranean area
in the construction of the pharmaceutical industrial framework was
key to the conformation of a model with its own identity, strongly par-
ticipated by professional corporations and with the industrial solu-
tions or recipes, exportable to modest pharmaceutical laboratories as
well as proceeding from these, a mechanism of reciprocity which re-
minds us how originally the laboratory of pharmaceutical specialities
was no more than a prolongation of the dispensary.
The industrialisation of medicines has been effected by two differ-
ent models. Central European countries, involved themselves in the
manufacture of large-scale pharmaceutical specialities taking advan-
tage of the important advances in Chemistry and Technology. On the
other hand, the Europe nations around the Mediterranean area, tried
to accelerate and benefit from their traditional procedures of manu-
al elaboration, using apparatus and machinery that, in general, only
permitted the mechanisation of some of the productive stages.
The triumphant model was that of the Central European countries,
essentially for its capacity to respond to the principal industrialisa-
tion criteria: mechanisation, re-productivity, profitability, wholesale
elaboration, tendency to the implantation of a single productive
process and the use of machinery of continuous function. Their most
important innovations, tablets and hard gelatine capsules are today,
two of the predominant pharmaceutical forms.
The model of the European-Mediterranean countries, although, on
occasion, complying with some of the necessary conditions for large-
scale fabrication, was never able to compete with the powerful Eng-
lish or German manufacturers. The idiosyncrasy itself of the French,
Spanish or Italian pharmaceutical collective, more prone to individu-
alised elaboration, would gag, limit and even cause the failure of its
own industrialisation prospects. Its two main contributions, the soft
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gelatine capsules and the amylaceous capsules disappeared from the
therapeutic map. Only the injectable vials, due to the hybridisation of
technologies between both models, have been able to survive.
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The ‘innovative’ model: The ‘traditional’ model: 
Centro-European area European-Mediterranean area
• Countries: Germany, England,
Switzerland.
• Basic chemical industry very devel-
oped, especially organic ones.
• Highly capitalised firms and with great
quantity of labour.
• Inclusion of highly qualified salaried
personnel.
• Clear separation between the property
(limited companies) and the technical
management.
• Integrated chemical industry: manufac-
ture of dyestuffs, explosives photogra -
phic material, perfumes and medicines.
• Inexistence of a pharmaceutical indus-
try with own identity. Exception: the in-
dustry based on vegetable active prin-
ciples.
• The essential of the drug is its active
pharmacological molecule; pharma-
ceutical form, the finished product, is
no more than a covering.
• The execution of the hegemony through
the industrial property: manufacturers
brand marks for the chemical sub-
stances.
• Secondary role of the pharmaceutical
in the global industrialisation process.
Principle protagonists: the investors
and chemical engineers.
• Countries; France, Spain, Italy.
• Chemical industry little developed and
the organic even less.
• Few highly capitalised firms and abun-
dance of labour.
• Deficient training in industrial chemis -
try: lack of qualified personnel.
• Tendency towards inter-professional
capitalisations: pharmaceutical capi-
tal. Separation between the owner of
the productive centre and the techni-
cal management did not exist.
• Typical industry of consumer goods: ex-
clusive manufacture of drugs. Inexis -
tence of a global industrial organigram.
• Pharmaceutical industry with own
identity. Place of manufacture: dispen-
saries, dependent and independent
laboratories.
• The ‘covering’ of the drug is the pri-
mordial aim, the active pharmacolog-
ical substances are no more than raw
materials.
• Industrial protection is effected through
the trademark of the establishment or
pharmaceutical speciality.
• The pharmaceutical is the protagonist
of the industrialising process.
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